Heron Therapeutics, Inc. (HRTX): Revenue
$154.90M
Year ended 2025-12-31
$151.18M
Trailing 12 months to 2026-06-30
+12.9%
3-year compound annual growth
+11.8%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $154.90M | +7.4% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $144.28M | +13.6% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $127.04M | +18.0% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $107.67M | +24.7% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $86.35M | -2.6% | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | $88.64M | -39.3% | 2022-02-28, From 2020-01-01 |
| 2019-12-31 | $145.97M | +88.4% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $77.47M | +151.8% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $30.77M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $1.28M | n/a | 2019-02-22, From 2016-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $154.90M | +7.4% |
| Liquidia Corp (LQDA) | 2025-12-31 | $158.32M | n/m |
| Macrogenics Inc (MGNX) | 2025-12-31 | $149.50M | -0.3% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $148.87M | +77.1% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $146.07M | +0.6% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $172.35M | +627.8% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $175.11M | +216.9% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $176.18M | +12.4% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $182.59M | -20.1% |
Compare HRTX, LQDA, MGNX, ELTP side by side · Screen every company in Pharmaceutical Preparations ↗